Literature DB >> 10882374

Synthesis and antiviral evaluation of halogenated beta-D- and -L-erythrofuranosylbenzimidazoles.

K S Gudmundsson1, J Tidwell, N Lippa, G W Koszalka, N van Draanen, R G Ptak, J C Drach, L B Townsend.   

Abstract

A series of 2-substituted benzimidazole D- and L-erythrofuranosyl nucleosides were synthesized and tested for activity against herpesviruses and for cytotoxicity. The D-nucleosides 2,5, 6-trichloro-1-(beta-D-erythrofuranosyl)benzimidazole (8a) and 2-bromo-5,6-dichloro-1-(beta-D-erythrofuranosyl)benzimidazole (8b) were prepared by coupling 1,2,3-tri-O-acetyl-beta-D-erythrofuranose (D-6) with the appropriate benzimidazole, followed by removal of the acetyl protecting groups. The 2-isopropylamino (9), 2-cyclopropylamino (10), and 2-mercaptobenzyl (11) derivatives were synthesized by nucleophilic displacements of the C-2 chlorine in the benzimidazole moiety of 8a. The D-nucleoside 4-bromo-5, 6-dichloro-2-isopropylamino-1-(beta-D-erythrofuranosyl)benzimid azo le (17) was prepared by coupling D-6 with the appropriate benzimidazole. The L-erythrofuranosyl derivatives, 5, 6-dichloro-2-isopropylamino-1-(beta-L-erythrofuranosyl)benzimid azo le (21a), its 2-cyclopropylamino analogue (21b), and the 2-isopropylamino analogue (25), were prepared by coupling L-6 with the appropriate benzimidazole. Several of these new derivatives had very good activity against HCMV in plaque and yield reduction assays (IC(50) = 0.05-19 microM against the Towne strain of HCMV) and DNA hybridization assays. Very little activity was observed against other herpesviruses. This pattern is similar to the antiviral activity profile observed for the corresponding ribofuranosides 2,5, 6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole (4a), its 2-bromo analogue (4b), and the 2-cyclopropylamino analogue (4c). In comparison, 8a was 15-fold more active against HCMV than 4a, and 8b was 4-fold more active against HCMV than 4b. The 5, 6-dichloro-2-isopropylamino-1-(beta-L-erythrofuranosyl)benzimid azo le (21a) was less active than 4c, which is now in clinical trials for HCMV infection. Both 8a,b had comparable HCMV activity to 4c. Mode of action studies with the D-erythrose analogues established that 8b acted by inhibition of viral DNA processing whereas 9 and 10 may act via a different mechanism. The lack of a 5'-hydroxymethyl group in all members of this series established that antiviral activity occurred without 5'-phosphorylation, a feature required for the activity of most nucleoside analogues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882374     DOI: 10.1021/jm990195p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Authors:  Paula M Krosky; Katherine Z Borysko; M Reza Nassiri; Rodrigo V Devivar; Roger G Ptak; Michelle G Davis; Karen K Biron; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Benzimidazole analogs inhibit human herpesvirus 6.

Authors:  Mark N Prichard; Samuel L Frederick; Shannon Daily; Katherine Z Borysko; Leroy B Townsend; John C Drach; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

3.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.

Authors:  David L Evers; Gloria Komazin; Roger G Ptak; Dongjin Shin; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  4-[1-(4-Cyano-benz-yl)-1H-benzimidazol-2-yl]benzonitrile.

Authors:  Reza Kia; Hoong-Kun Fun; Hadi Kargar
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-03-06

6.  Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.

Authors:  Earl R Kern; Caroll B Hartline; Rachel J Rybak; John C Drach; Leroy B Townsend; Karen K Biron; Deborah J Bidanset
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Inhibition of hepatitis B virus by a novel L-nucleoside, beta-L-D4A and related analogues.

Authors:  Jin-Ming Wu; Ju-Sheng Lin; Na Xie; Kuo-Huan Liang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

8.  In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

Authors:  Stephanie L Williams; Caroll B Hartline; Nicole L Kushner; Emma A Harden; Deborah J Bidanset; John C Drach; Leroy B Townsend; Mark R Underwood; Karen K Biron; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.

Authors:  Jacob P Lalezari; Judith A Aberg; Laurene H Wang; Mary Beth Wire; Richard Miner; Wendy Snowden; Christine L Talarico; Shuching Shaw; Mark A Jacobson; W Lawrence Drew
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Ethyl 1-benzyl-1,2,3,3a,4,10b-hexa-hydro-pyrrolo-[2',3':3,4]pyrrolo-[1,2-a]benzimidazole-2-carboxyl-ate.

Authors:  Liping Meng; James C Fettinger; Mark J Kurth
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.